<DOC>
	<DOCNO>NCT00640991</DOCNO>
	<brief_summary>Insulin safely reduce glucose level patient acute ST-elevation myocardial infarction admission hyperglycemia .</brief_summary>
	<brief_title>REsearching Coronary REduction Appropriately Targeting Euglycemia ( RECREATE Pilot Study )</brief_title>
	<detailed_description>Patients randomly assign either control arm receive usual AMI care experimental arm , include routine AMI care well intensive therapy intervention . In addition capillary blood glucose measurement obtain titrate insulin dos experimental arm patient , laboratory plasma glucose drawn patient randomization , 10 , 24 , 48 , 72 hour post randomization , 7 day post randomization ( hospital discharge occur first ) , 30 day post randomization .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Both nondiabetic patient patient noninsulinrequiring type 2 diabetes mellitus admit suspect AMI eligible meet follow criterion : Signs symptom AMI definite ECG change , define persistent STsegment elevation ( &gt; = 1 mm ) two contiguous lead , new leave bundle branch block Onset symptom within 24 hour hospital presentation Capillary blood glucose level presentation &gt; = 8.0 mmol/L ( 144 mg/dL ) Patient condition REQUIRE administration insulin , include : Type 1 diabetes mellitus , define documented history diabetes mellitus age 30 Type 2 diabetes mellitus treat insulin prior AMI presentation Type 2 diabetes mellitus know poorly control ( e.g . admission capillary blood glucose &gt; 16.0 mmol/L ( 288 mg/dL ) mark elevation glucose site investigator plan treat insulin therapy ) A history severe hypoglycemic episode ( define hypoglycemia symptom patient unable reverse without assistance another person ) within past two year Known suspected endstage liver disease ( due risk hypoglycemia set liver dysfunction consequent impaired regulation glucose homeostasis ) Cardiogenic shock admission ( due inaccuracy glucose meter reading ) Documented pregnancy Any concomitant disease ( e.g . cancer ) might limit life expectancy le 90 day Anticipated poor adherence study treatment factor might jeopardize 90day followup ( e.g . fix address , long distance hospital , etc . ) Prior enrollment trial current enrollment another trial STsegment elevation myocardial infarction</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Clinical Trial</keyword>
	<keyword>Insulin</keyword>
</DOC>